PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in cardiovascular and cardiopulmonary therapies. Their pipeline includes a reversal agent for ticagrelor, a treatment for major bleeding or urgent surgery, a fusion protein for pulmonary arterial hypertension, and an oral agent for resistant hypertension. They utilize their elastin-like polypeptide technology platform to develop therapies with improved dosing and pharmacokinetics. The company is based in Malvern, Pennsylvania.